Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

  • This release includes the following COVID-19 updates:
    • Updates have been made to expand age ranges down to >=12 years old for the Pfizer COVID-19 Vaccine (CVX 208).
    • Recommendations have been updated For patients with no prior doses of COVID-19 vaccine, updated recommendations to recommend COVID-19 vaccine to patients >= 12 years old  
      • Note - ICE previously had a conditional recommendation for patients with no prior doses of COVID-19 vaccine
    • Support has been added to handle AstraZeneca COVID-19 vaccine (CVX 210) shots reported on the patient record.
      • As of now, the AstraZeneca COVID-19 vaccine has not yet been FDA approved in the U.S. , but is approved by the WHO. See COVID-19 Vaccine Group page for details.
      • When the FDA approves the AstraZeneca COVID-19 vaccine (CVX 210) for use in the U.S., ICE will be updated as necessary.
  • In addition to the above updates, added evaluation reason code VACCINE_NOT_APPROVED_IN_US to the ICE Implementation Guide. 
  • Note: This is implementation of COVID-19 Vaccine Group in ICE based on interim recommendations from ACIP.  As additional guidelines from ACIP are published and/or vaccines become available, the COVID-19 logic in ICE will be updated.

...